PharmaMar is a biopharmaceutical company with headquarters in Madrid (Spain) and laboratories in Cambridge (US). PharmaMar is fully owned by the Zeltia Group and traded on the Spanish Stock Exchange (ZEL) with a market capitalization of over 1 Billion euros. Founded in 1986, with the vision of exploiting the great potential of the oceans as a source of novel medicines for improved cancer treatment. PharmaMar has a unique collection of 42.000 marine organisms obtained from expeditions around the world. 7000 new chemical entities have been discovered and 30 new families of compounds have been identified. PharmaMar also has 3 molecules in advanced preclinical development.